GB201810181D0 - Cells expressing chimeric recominant growth factor receptors - Google Patents

Cells expressing chimeric recominant growth factor receptors

Info

Publication number
GB201810181D0
GB201810181D0 GBGB1810181.6A GB201810181A GB201810181D0 GB 201810181 D0 GB201810181 D0 GB 201810181D0 GB 201810181 A GB201810181 A GB 201810181A GB 201810181 D0 GB201810181 D0 GB 201810181D0
Authority
GB
United Kingdom
Prior art keywords
recominant
growth factor
cells expressing
factor receptors
expressing chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1810181.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instil Bio UK Ltd
Original Assignee
Immetacyte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63042840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201810181(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immetacyte Ltd filed Critical Immetacyte Ltd
Priority to GBGB1810181.6A priority Critical patent/GB201810181D0/en
Publication of GB201810181D0 publication Critical patent/GB201810181D0/en
Priority to MX2020014257A priority patent/MX2020014257A/es
Priority to JP2020570748A priority patent/JP2021527425A/ja
Priority to EA202190100A priority patent/EA202190100A1/ru
Priority to CN201980055314.2A priority patent/CN112601759A/zh
Priority to PCT/GB2019/051745 priority patent/WO2019243835A1/en
Priority to CA3104079A priority patent/CA3104079A1/en
Priority to KR1020217001790A priority patent/KR20210022690A/ko
Priority to CR20200624A priority patent/CR20200624A/es
Priority to EP19739687.2A priority patent/EP3810646A1/en
Priority to BR112020026233-1A priority patent/BR112020026233A2/pt
Priority to AU2019289202A priority patent/AU2019289202B2/en
Priority to SG11202012726QA priority patent/SG11202012726QA/en
Priority to IL279469A priority patent/IL279469A/en
Priority to US17/124,922 priority patent/US20210205365A1/en
Priority to ECSENADI202082338A priority patent/ECSP20082338A/es
Priority to PH12020500678A priority patent/PH12020500678A1/en
Priority to CL2020003319A priority patent/CL2020003319A1/es
Priority to CONC2020/0016052A priority patent/CO2020016052A2/es
Priority to JP2024102884A priority patent/JP2024156656A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
GBGB1810181.6A 2018-06-21 2018-06-21 Cells expressing chimeric recominant growth factor receptors Ceased GB201810181D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1810181.6A GB201810181D0 (en) 2018-06-21 2018-06-21 Cells expressing chimeric recominant growth factor receptors
AU2019289202A AU2019289202B2 (en) 2018-06-21 2019-06-21 Chimeric growth factor receptors
SG11202012726QA SG11202012726QA (en) 2018-06-21 2019-06-21 Chimeric growth factor receptors
EP19739687.2A EP3810646A1 (en) 2018-06-21 2019-06-21 Chimeric growth factor receptors
BR112020026233-1A BR112020026233A2 (pt) 2018-06-21 2019-06-21 receptores de fator de crescimento quimérico
EA202190100A EA202190100A1 (ru) 2018-06-21 2019-06-21 Химерные рецепторы факторов роста
CN201980055314.2A CN112601759A (zh) 2018-06-21 2019-06-21 嵌合生长因子受体
PCT/GB2019/051745 WO2019243835A1 (en) 2018-06-21 2019-06-21 Chimeric growth factor receptors
CA3104079A CA3104079A1 (en) 2018-06-21 2019-06-21 Chimeric growth factor receptors
KR1020217001790A KR20210022690A (ko) 2018-06-21 2019-06-21 키메라 성장 인자 수용체
CR20200624A CR20200624A (es) 2018-06-21 2019-06-21 Receptores del factor de crecimiento quimérico
MX2020014257A MX2020014257A (es) 2018-06-21 2019-06-21 Receptores del factor de crecimiento quimérico.
JP2020570748A JP2021527425A (ja) 2018-06-21 2019-06-21 キメラ増殖因子受容体
IL279469A IL279469A (en) 2018-06-21 2020-12-15 Chimeric growth factor receptors
US17/124,922 US20210205365A1 (en) 2018-06-21 2020-12-17 Chimeric Growth Factor Receptors
ECSENADI202082338A ECSP20082338A (es) 2018-06-21 2020-12-18 Receptores del factor de crecimiento quimérico
PH12020500678A PH12020500678A1 (en) 2018-06-21 2020-12-18 Chimeric growth factor receptors
CL2020003319A CL2020003319A1 (es) 2018-06-21 2020-12-21 Receptores del factor de crecimiento quiméricos
CONC2020/0016052A CO2020016052A2 (es) 2018-06-21 2020-12-21 Receptores del factor de crecimiento quimérico
JP2024102884A JP2024156656A (ja) 2018-06-21 2024-06-26 キメラ増殖因子受容体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1810181.6A GB201810181D0 (en) 2018-06-21 2018-06-21 Cells expressing chimeric recominant growth factor receptors

Publications (1)

Publication Number Publication Date
GB201810181D0 true GB201810181D0 (en) 2018-08-08

Family

ID=63042840

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1810181.6A Ceased GB201810181D0 (en) 2018-06-21 2018-06-21 Cells expressing chimeric recominant growth factor receptors

Country Status (19)

Country Link
US (1) US20210205365A1 (enExample)
EP (1) EP3810646A1 (enExample)
JP (2) JP2021527425A (enExample)
KR (1) KR20210022690A (enExample)
CN (1) CN112601759A (enExample)
AU (1) AU2019289202B2 (enExample)
BR (1) BR112020026233A2 (enExample)
CA (1) CA3104079A1 (enExample)
CL (1) CL2020003319A1 (enExample)
CO (1) CO2020016052A2 (enExample)
CR (1) CR20200624A (enExample)
EA (1) EA202190100A1 (enExample)
EC (1) ECSP20082338A (enExample)
GB (1) GB201810181D0 (enExample)
IL (1) IL279469A (enExample)
MX (1) MX2020014257A (enExample)
PH (1) PH12020500678A1 (enExample)
SG (1) SG11202012726QA (enExample)
WO (1) WO2019243835A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
WO2021173586A1 (en) * 2020-02-24 2021-09-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
CA3205464A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4370139A4 (en) 2021-07-14 2025-10-15 Synthekine Inc METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
CN122094708A (zh) * 2023-10-03 2026-05-26 美国政府(由卫生和人类服务部的部长所代表) 表达嵌合造血生长因子受体的nk细胞或t细胞及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20011026A3 (cs) * 1998-09-23 2001-08-15 Zymogenetics, Inc. Izolovaný polynukleotid, expresní vektor, kultivovaná buňka, konstrukt DNA, způsob produkce proteinu, izolovaný polypeptid, způsob produkce protilátky, protilátka a způsob detekce
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2015188141A2 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
WO2018175476A1 (en) * 2017-03-20 2018-09-27 Baylor College Of Medicine Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells

Also Published As

Publication number Publication date
KR20210022690A (ko) 2021-03-03
AU2019289202B2 (en) 2024-10-31
SG11202012726QA (en) 2021-01-28
ECSP20082338A (es) 2021-02-26
US20210205365A1 (en) 2021-07-08
CO2020016052A2 (es) 2021-01-29
EP3810646A1 (en) 2021-04-28
CR20200624A (es) 2021-06-24
MX2020014257A (es) 2021-07-21
JP2021527425A (ja) 2021-10-14
CL2020003319A1 (es) 2021-07-09
BR112020026233A2 (pt) 2021-04-20
PH12020500678A1 (en) 2021-07-12
JP2024156656A (ja) 2024-11-06
AU2019289202A1 (en) 2021-01-14
CA3104079A1 (en) 2019-12-26
CN112601759A (zh) 2021-04-02
WO2019243835A1 (en) 2019-12-26
EA202190100A1 (ru) 2021-04-23
IL279469A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
SG11202107708XA (en) Gprc5d chimeric antigen receptors and cells expressing the same
IL277414A (en) NK-92 cells with chimeric antigen receptor modification
IL276831A (en) Chimeric inducible cytokine receptors
IL279469A (en) Chimeric growth factor receptors
SG11202009284TA (en) T cell receptors and engineered cells expressing same
SMT202300171T1 (it) Recettori di cellule t
SG10201913655UA (en) Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
IL289921A (en) Cells express chimeric antigen receptors and chimeric stimulatory receptors and their functions
EP3134434A4 (en) Kappa/lambda chimeric antigen receptors
ZA202005837B (en) Cd83-binding chimeric antigen receptors
EP3752197A4 (en) NKG2D CHIMERIC ANTIGEN RECEPTORS
IL286644A (en) Genetically reprogrammed tregs expressing cars
SG11202103981XA (en) Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells
IL281088A (en) Flt3l-based chimeric proteins
GB201711470D0 (en) Chimeric receptors
PL3531481T3 (pl) Kompozytowe materiały elektrod
EP3986442A4 (en) Chimeric protein expressing t-cells
GB201806084D0 (en) Antibodies
IL277859A (en) Chimeric NOTCH receptors
HK40053670A (zh) 嵌合生长因子受体
GB201915375D0 (en) HLA-independent t cell receptors
GB201820078D0 (en) T cell receptors
HK40075506A (en) Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof
HK40073724A (en) Chimeric protein expressing t-cells
HK40043339A (zh) 嵌合notch受体

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)